Loading clinical trials...
Loading clinical trials...
Posture Stability and Functional Activity Changes After Transcranial Photobiomodulation for Patients With Parkinson's Disease: A Randomized Controlled Trial
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is a progressive and disabling disease with significative impact on quality of life. Since it has no cure, available treatment is targeted to improve the symptoms due to a lack of dopamine in the central nervous system. The aim of the study was to see how transcranial photobiomodulation (tPBM) helped patients with Parkinson's disease.
Age
50 - 70 years
Sex
ALL
Healthy Volunteers
No
Al Zaytoonah University
Amaan, Jordan
Start Date
December 15, 2024
Primary Completion Date
March 20, 2025
Completion Date
April 3, 2025
Last Updated
April 8, 2025
38
ACTUAL participants
transcranial photobiomodulation
DEVICE
exercises training
OTHER
Lead Sponsor
Al-Zaytoonah University of Jordan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06113640